Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2016

16.10.2015

Hypereosinophilic Syndrome

verfasst von: Casey Curtis, Princess Ogbogu

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Hypereosinophilic syndrome consists of a group of disorders characterized by abnormal accumulation of eosinophils in the blood or peripheral tissues, independent of known secondary causes of eosinophilia such as parasitic infection. Clinical manifestations of the condition are highly variable, ranging from asymptomatic eosinophilia to severe tissue damage and end-organ failure. This entity has been recognized for decades, with early studies identifying distinct groups of patients with differing symptoms, exam findings, laboratory abnormalities, and prognosis. In the past, these patients were treated with non-targeted immunosuppressive agents, often with limited efficacy. More recently, advances in the knowledge of eosinophil biology and molecular diagnostics have allowed for more specific delineation of the many disease subgroups that characterize hypereosinophilic syndrome. Identification of these groups has led to a personalized management approach to the condition, with improved diagnostic techniques as well as stratification of patients into more effective treatment groups. This review will discuss the evolution of the definition of hypereosinophilic syndrome, outline current disease classifications, provide a guide for evaluation and monitoring, and discuss current and future therapeutic modalities.
Literatur
1.
Zurück zum Zitat Gotlib J (2011) World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86:678–688CrossRef Gotlib J (2011) World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86:678–688CrossRef
2.
Zurück zum Zitat Chusid MJ, Dale CD, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1–27CrossRef Chusid MJ, Dale CD, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1–27CrossRef
3.
Zurück zum Zitat Klion AD, Bochner BS, Gleich GJ et al (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary reports. J Allergy Clin Immunol 117:1292–1302CrossRefPubMed Klion AD, Bochner BS, Gleich GJ et al (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary reports. J Allergy Clin Immunol 117:1292–1302CrossRefPubMed
4.
8.
Zurück zum Zitat Criado PR, Avancini J, Santi CG et al (2012) Drug reaction with eosinophilia and systemic symptoms (DRESS): a complex interaction of drugs, viruses, and the immune system. Isr Med Assoc J 14:577–582PubMed Criado PR, Avancini J, Santi CG et al (2012) Drug reaction with eosinophilia and systemic symptoms (DRESS): a complex interaction of drugs, viruses, and the immune system. Isr Med Assoc J 14:577–582PubMed
12.
Zurück zum Zitat Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83(10):2759–2779PubMed Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83(10):2759–2779PubMed
13.
Zurück zum Zitat Flaum MA, Schooley RT, Fauci AS et al (1981) Clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 58:1012–1020PubMed Flaum MA, Schooley RT, Fauci AS et al (1981) Clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 58:1012–1020PubMed
14.
Zurück zum Zitat Kaplan MH, Hall WM, Susin M et al (1991) Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection. Am J Med 91:300–309CrossRefPubMed Kaplan MH, Hall WM, Susin M et al (1991) Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection. Am J Med 91:300–309CrossRefPubMed
15.
Zurück zum Zitat Harley WB, Blaser MJ (1994) Disseminated coccidioidomycosis associated with extreme eosinophilia. J Infect Dis 18:627–629 Harley WB, Blaser MJ (1994) Disseminated coccidioidomycosis associated with extreme eosinophilia. J Infect Dis 18:627–629
16.
Zurück zum Zitat Angelis M, Yu M, Takanishi D et al (1996) Eosinophilia as a marker of adrenal insufficiency in the surgical intensive care unit. J Am Coll Surg 183(6):589–596PubMed Angelis M, Yu M, Takanishi D et al (1996) Eosinophilia as a marker of adrenal insufficiency in the surgical intensive care unit. J Am Coll Surg 183(6):589–596PubMed
17.
Zurück zum Zitat Klion A (2009) Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 60:293–306CrossRefPubMed Klion A (2009) Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 60:293–306CrossRefPubMed
18.
Zurück zum Zitat Gleich GJ, Leiferman KM, Padanani A et al (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359(9317):1577–1578CrossRefPubMed Gleich GJ, Leiferman KM, Padanani A et al (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359(9317):1577–1578CrossRefPubMed
19.
Zurück zum Zitat Cools J, DeAngelo DJ, Gotlib J et al (2003) A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214CrossRefPubMed Cools J, DeAngelo DJ, Gotlib J et al (2003) A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214CrossRefPubMed
20.
Zurück zum Zitat Ogbogu PU, Bochner BS, Butterfield JH et al (2009) Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124(6):1319–1325CrossRefPubMedPubMedCentral Ogbogu PU, Bochner BS, Butterfield JH et al (2009) Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124(6):1319–1325CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Pardanani A, Ketterling RP, Li C-Y et al (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30(8):965–970CrossRefPubMed Pardanani A, Ketterling RP, Li C-Y et al (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30(8):965–970CrossRefPubMed
22.
Zurück zum Zitat Bain BJ, Gilliland DG, Horny H-P et al (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Serdlow S, Harris NL, Stein H et al (eds) World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. IARC Press, Lyon, pp 68–73 Bain BJ, Gilliland DG, Horny H-P et al (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Serdlow S, Harris NL, Stein H et al (eds) World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. IARC Press, Lyon, pp 68–73
23.
Zurück zum Zitat Tefferi A, Gotlib J, Pardanani A (2010) Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 85(2):158–164CrossRefPubMedPubMedCentral Tefferi A, Gotlib J, Pardanani A (2010) Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 85(2):158–164CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Roufosse F, Cogan E, Goldman M (2007) Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin N Am 27(3):551–560CrossRef Roufosse F, Cogan E, Goldman M (2007) Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin N Am 27(3):551–560CrossRef
25.
Zurück zum Zitat Cogan E, Roufosse F (2012) Clinical management of the hypereosinophilic syndromes. Expert Rev Hematol 5(3):275–290CrossRefPubMed Cogan E, Roufosse F (2012) Clinical management of the hypereosinophilic syndromes. Expert Rev Hematol 5(3):275–290CrossRefPubMed
26.
Zurück zum Zitat Lin AY, Nutman TB, Kaslow D et al (1998) Familial eosinophilia: clinical and laboratory characteristics of a U.S. kindred. Am J Med Genet 76:229–237CrossRefPubMed Lin AY, Nutman TB, Kaslow D et al (1998) Familial eosinophilia: clinical and laboratory characteristics of a U.S. kindred. Am J Med Genet 76:229–237CrossRefPubMed
27.
Zurück zum Zitat Rious JD, Stone VA, Daly MJ et al (1998) Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet 63:1086–1094CrossRef Rious JD, Stone VA, Daly MJ et al (1998) Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet 63:1086–1094CrossRef
29.
Zurück zum Zitat Furuta GT, Forbes D, Boey C et al (2008) Eosinophilic gastrointestinal diseases (EGIDs). J Pediatr Gastroenterol Nutr 47:234–238CrossRefPubMed Furuta GT, Forbes D, Boey C et al (2008) Eosinophilic gastrointestinal diseases (EGIDs). J Pediatr Gastroenterol Nutr 47:234–238CrossRefPubMed
30.
Zurück zum Zitat Gleich GJ, Schroeter AL, Marcoux JP et al (1984) Episodic angioedema associated with eosinophilia. N Engl J Med 310(25):1621–1626CrossRefPubMed Gleich GJ, Schroeter AL, Marcoux JP et al (1984) Episodic angioedema associated with eosinophilia. N Engl J Med 310(25):1621–1626CrossRefPubMed
31.
Zurück zum Zitat Khoury P, Herold J, Alpaugh A et al (2014) Episodic angioedema with eosinophilia (Gleich’s syndrome) is a multilineage cell-cycling disorder. Haematologica 100(3):300–307CrossRefPubMed Khoury P, Herold J, Alpaugh A et al (2014) Episodic angioedema with eosinophilia (Gleich’s syndrome) is a multilineage cell-cycling disorder. Haematologica 100(3):300–307CrossRefPubMed
32.
Zurück zum Zitat Valent PV, Klion A, Horny H-P et al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130(3):607–612.e9CrossRefPubMedPubMedCentral Valent PV, Klion A, Horny H-P et al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130(3):607–612.e9CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Leiferman KM, Gleich GJ, Peters MS (2007) Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin N Am 27(3):415–441CrossRef Leiferman KM, Gleich GJ, Peters MS (2007) Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin N Am 27(3):415–441CrossRef
34.
Zurück zum Zitat Ogbogu PU, Rosing DR, McDonald KH (2007) Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin N Am 27(3):457–475CrossRef Ogbogu PU, Rosing DR, McDonald KH (2007) Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin N Am 27(3):457–475CrossRef
35.
Zurück zum Zitat Spry CJF, Davies J, Tai PC et al (1983) Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 52(1):1–22PubMed Spry CJF, Davies J, Tai PC et al (1983) Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 52(1):1–22PubMed
36.
Zurück zum Zitat Moore PM, Harley JB, Fauci AS (1985) Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 102(1):109–114CrossRefPubMed Moore PM, Harley JB, Fauci AS (1985) Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 102(1):109–114CrossRefPubMed
37.
Zurück zum Zitat Wechsler ME (2007) Pulmonary eosinophilic syndromes. Immunol Allergy Clin N Am 27(3):477–492CrossRef Wechsler ME (2007) Pulmonary eosinophilic syndromes. Immunol Allergy Clin N Am 27(3):477–492CrossRef
38.
Zurück zum Zitat Khoury P, Grayson PC, Klion AD (2014) Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol 10:474–483CrossRefPubMed Khoury P, Grayson PC, Klion AD (2014) Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol 10:474–483CrossRefPubMed
39.
Zurück zum Zitat Zuo L, Rothenberg ME (2007) Gastrointestinal eosinophilia. Immunol Allergy Clin N Am 27(3):443–455CrossRef Zuo L, Rothenberg ME (2007) Gastrointestinal eosinophilia. Immunol Allergy Clin N Am 27(3):443–455CrossRef
40.
Zurück zum Zitat Parrillo JE, Fauci AS, Wolff SM (1977) The hypereosinophilic syndrome: dramatic response to therapeutic intervention. Trans Assoc Am Phys 90:135–144PubMed Parrillo JE, Fauci AS, Wolff SM (1977) The hypereosinophilic syndrome: dramatic response to therapeutic intervention. Trans Assoc Am Phys 90:135–144PubMed
41.
Zurück zum Zitat Bush RK, Geller M, Busse WW et al (1978) Response to corticosteroids in the hypereosinophilic syndrome. Associated with increased serum IgE levels. Arch Intern Med 138:1244–1246CrossRefPubMed Bush RK, Geller M, Busse WW et al (1978) Response to corticosteroids in the hypereosinophilic syndrome. Associated with increased serum IgE levels. Arch Intern Med 138:1244–1246CrossRefPubMed
42.
Zurück zum Zitat de Lavareille A, Roufosse F, Schmid-Grendelmeier P et al (2002) High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 110:476–479CrossRefPubMed de Lavareille A, Roufosse F, Schmid-Grendelmeier P et al (2002) High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 110:476–479CrossRefPubMed
43.
Zurück zum Zitat Dahabreh JJ, Giannouli S, Zoi C et al (2007) Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) 86(6):344–354CrossRef Dahabreh JJ, Giannouli S, Zoi C et al (2007) Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) 86(6):344–354CrossRef
44.
Zurück zum Zitat Zielinski RM, Lawrence WD (1990) Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med 113(9):716–718CrossRefPubMed Zielinski RM, Lawrence WD (1990) Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med 113(9):716–718CrossRefPubMed
46.
Zurück zum Zitat Sadovnik I, Lierman E, Peter B et al (2014) Identification of ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Exp Hematol 42:282–293CrossRefPubMedPubMedCentral Sadovnik I, Lierman E, Peter B et al (2014) Identification of ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Exp Hematol 42:282–293CrossRefPubMedPubMedCentral
47.
48.
Zurück zum Zitat Rothenberg ME, Klion AD, Roufosse FE et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215–1228CrossRefPubMed Rothenberg ME, Klion AD, Roufosse FE et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215–1228CrossRefPubMed
49.
Zurück zum Zitat Roufosse F, Kahn J-E, Gleich GJ et al (2013) Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 131:461–467CrossRefPubMedPubMedCentral Roufosse F, Kahn J-E, Gleich GJ et al (2013) Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 131:461–467CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Kiwamoto T, Kawasaki N, Paulson JC et al (2012) Siglec-8 as a drug able target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 135:327–336CrossRefPubMedPubMedCentral Kiwamoto T, Kawasaki N, Paulson JC et al (2012) Siglec-8 as a drug able target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 135:327–336CrossRefPubMedPubMedCentral
Metadaten
Titel
Hypereosinophilic Syndrome
verfasst von
Casey Curtis
Princess Ogbogu
Publikationsdatum
16.10.2015
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2016
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-015-8506-7

Weitere Artikel der Ausgabe 2/2016

Clinical Reviews in Allergy & Immunology 2/2016 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.